Biogen Inc.

Total Valuation

Biogen Inc. carries a market capitalization of 33.17B, placing it among publicly traded companies globally. Its enterprise value stands at 38.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Biogen Inc. currently has 147.70M shares outstanding.

Valuation Ratios

Biogen Inc. trades at a trailing price-to-earnings ratio of 38.07. The price-to-sales ratio is 3.17, and the price-to-book ratio stands at 1.69.

Enterprise Valuation

On an enterprise value basis, Biogen Inc. trades at an EV/EBITDA multiple of 14.03 and an EV/FCF ratio of 11.13. The EV/Sales ratio of 3.89 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.15 provides insight into valuation relative to core operating earnings.

Financial Position

Biogen Inc. maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 44.33, indicating elevated leverage, while an interest coverage ratio of 9.75 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Biogen Inc. posts a return on equity of 4.58 and a return on invested capital of 6.18.

Taxes

Over the trailing twelve months, Biogen Inc. has paid 176.80M in income taxes, reflecting an effective tax rate of 17.48.

Stock Price Statistics

Biogen Inc.'s stock has gained approximately 58.52987% over the past 52 weeks. The 50-day moving average sits at 208.65, while the 200-day moving average is 190.48.

Income Statement

Over the trailing twelve months, Biogen Inc. generated 10.03B in revenue and converted that into 834.60M in net income, yielding earnings per share of 5.65. EBITDA reached 2.78B, while operating income came in at 1.93B.

Balance Sheet

Biogen Inc. holds 1.29B in cash and equivalents against 8.36B in total debt, resulting in a net debt position of 6.81B. Total book value stands at 18.85B, with working capital of 3.39B providing operational flexibility.

Cash Flow

Biogen Inc. produced 2.88B in operating cash flow over the past twelve months. After subtracting -388.80M in capital expenditures, free cash flow totaled 2.49B - equivalent to 16.93 per share.

Margins

Biogen Inc. operates with a gross margin of 73.99, reflecting its pricing power and cost economics. The operating margin of 19.29 and net profit margin of 8.32 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Biogen Inc.'s most recent stock split took place on January 18, 2001 with a 1:3 split ratio.

Scores

Biogen Inc. posts an Altman Z-Score of 5.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.